- The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study
This study showed CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases
- Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study
In 80 in-patients receiving a combination of hydroxychloroquine and azithromycin authors noted a clinical improvement in all but one 86 year-old patient who died, and one 74 year- old patient still in ICU. A rapid fall of nasopharyngeal viral load tested by qPCR was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% patients at Day5. These results allowed patients to be rapidly discharged from contagious wards with a mean length of stay of five days. A modified National Early Warning Score [NEWS] was calculated and added age and temperature to characterize the severity of Covid-19 patients in the study. The NEWS score is one measure to facilitate cross study comparisons of future studies that are needed to replicate this exploratory study with adequate control groups.
- Landscape of SARS-CoV-2 vaccine candidates
A pdf from WHO listing vaccines in clinical (2) and pre-clinical (48) evaluation.
- UnitedHealth Group pushes self-collected COVID-19 test
In a study of 500 patients at UnitedHealth’s network of clinics in Seattle, diagnostic tests for SARS-CoV-2 accurately detected virus in more than 90% of known positive patients.
World Health Organization (WHO)
Novel Coronavirus (COVID-19) Situation from World Health Organization (WHO)
Johns Hopkins University (JHU)
Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at JHU
COVID-19 in US and Canada
1Point3Acres Real-Time Coronavirus (COVID-19) Updates in US and Canada with Credible Sources
Genomic Epidemiology COVID-19
Genomic Epidemiology of (COVID-19) Maintained by the Nextstrain team, enabled by data from GISAID.